为了对临床药理学影响的定量理解:人口药动力学建模
Donghong Xu1, Hanbin Li2, Stephen B Heitner3
1Clinical Pharmacology, Cytokinetics, South San Francisco, California, USA.
阿菲卡门特是一种心脏肌肉酶抑制剂,用于过度缩放性心肌病 (HCM),显示出可预测的药理动力学. 体重,性别和健康状况会影响胺暴露,但变化率仍然很低.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 药物开发 药物开发
背景情况:
- 增高性心肌病变 (HCM) 是一种遗传性心脏病.
- 阿菲卡门是用于HCM治疗的试验性口服心脏肌肉酶抑制剂.
- 了解aficamten的药理动力学 (PK) 概况对于优化其使用至关重要.
研究的目的:
- 为了描述aficamten的种群药理动力学 (PK).
- 为了确定影响HCM患者的aficamten暴露的共变量.
- 评估aficamten的PK配置文件的可预测性和可变性.
主要方法:
- 使用来自九项临床研究的数据开发了一个人群PK模型.
- 使用了一种具有线性淘汰和第一阶吸收的2分隔模型.
- 共变量分析发现了影响aficamten暴露的重要因素.
主要成果:
- 阿菲卡门特表现出线性和可预测的PK概况,个人间差异性较低.
- 体重,性别和人口 (健康与HCM) 是影响暴露的显著共变量.
- 56公斤的男性患者的AUCtau比80公斤的男性高23%;女性的AUCtau比同体重的男性高14.7%.
结论:
- 阿菲卡门特表现出有利的PK特征,具有可预测的剂量暴露关系.
- 确定的共变因子可以为aficamten的个性化剂量策略提供信息.
- 低可变性支持aficamten作为慢性口服治疗HCM的潜力.
更多相关视频
10:02Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Analysis of Population Pharmacokinetic Data
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Mechanistic Models: Compartment Models in Individual and Population Analysis
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
